Business
IGC Pharma Introduces MINT-AD: Proprietary AI Platform to Predict Alzheimer's Risk and Accelerate Early Detection
- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics - POTOMAC, MD / ACCESS Newswire / July 10, 2025 /IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"- Multimodal foundation model enables personalized cognitive forecasts and expands access to Alzheimer's diagnostics -","length":122,"tagName":"p"},{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / July 10, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced the development of MINT-AD, Multimodal Interpretable Transformer for Alzheimer's, the Company's proprietary AI-powered diagnostic platform designed to identify individuals at high risk of cognitive decline years before symptoms appear.","length":423,"tagName":"p"},{"type":"text","content":"MINT-AD leverages diverse data sources including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories. The platform is being designed for integration into physician workflows to help improve early detection, care personalization and clinical trial enrolment.","length":346,"tagName":"p"},{"type":"text","content":""We're excited to announce MINT-AD, a significant milestone in IGC Pharma's AI strategy and a major step forward in our fight against Alzheimer's disease," said Ram Mukunda, CEO of IGC Pharma. "MINT-AD has the potential to transform early diagnosis by giving physicians a powerful, clinically interpretable tool to identify high-risk individuals well before symptoms appear. This platform addresses a critical gap in Alzheimer's care while creating strong strategic synergy with our lead therapeutic candidate, IGC-AD1. Together, they position us to drive precision medicine in Alzheimer's disease with strategic partnerships, advancing both patient outcomes and long-term value for our shareholders."","length":741,"tagName":"p"},{"type":"text","content":"IGC expects to launch a beta version of MINT-AD in Fiscal 2026 for pilot evaluation in collaboration with academic and clinical partners. Planned use cases for the platform include integration into electronic health records (EHR) or web-based tools for diagnostic support, enhancing patient stratification, including for our clinical trials, and enabling scalable cognitive assessments in resource-limited settings.","length":415,"tagName":"p"},{"type":"text","content":"Why MINT-AD Matters: Addressing a Global Di...